Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigator-initiated Phase I Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer

NCT06853496 is registered in ClinicalTrials.gov with Eiji Shinozaki as lead sponsor.

NCT NCT06853496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06853496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigator-initiated Phase I Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer
Lead sponsor
Eiji Shinozaki
Phase
Phase 1
Overall status
Recruiting
Start date
March 13, 2025
Completion date
March 31, 2027
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable colorectal neoplasm metastasis